Drug Marketing in Focus: Risk Monitoring Now Mandatory for Promotional Activities and More Pharmaceutical Businesses Subject to BPOM Oversight

The National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan– “ BPOM ”) has issued Regulation No. 7 of 2026 on the Promotion and Advertising of Drugs (“ Regulation 7/2026 ”). This framework has now repealed and replaced Regulation of the BPOM No. 2 of 2021 on Guidelines for Drug Advertising (“ Regulation 2/2021 ”), while retaining existing advertising approvals, meaning that approvals that were secured under Regulation 7/2026 will remain valid. Businesses have been granted a 12-month compliance grace period that will run until 29 April 2027 in order to bring their advertisements and promotional materials into line with the new framework. [1]